Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Diabetes knowledge and its determinants in a Mexican population.
Bautista-Martinez S, Aguilar-Salinas CA, Lerman I, Velasco ML, Castellanos R, Zenteno E, Guillen LE, Murcio R, Wong B, Gómez Pérez FJ, Rull-Rodrigo JA. Bautista-Martinez S, et al. Among authors: guillen le. Diabetes Educ. 1999 May-Jun;25(3):374-81. doi: 10.1177/014572179902500308. Diabetes Educ. 1999. PMID: 10531857
Acarbose vs. bedtime NPH insulin in the treatment of secondary failures to sulphonylurea-metformin therapy in type 2 diabetes mellitus.
López-Alvarenga JC, Aguilar-Salinas CA, Velasco-Perez ML, Arita-Melzer O, Guillen LE, Wong B, Brito G, Mercado V, Gómez-Pérez FJ, Rull-Rodrigo JA. López-Alvarenga JC, et al. Among authors: guillen le. Diabetes Obes Metab. 1999 Jan;1(1):29-35. doi: 10.1046/j.1463-1326.1999.00007.x. Diabetes Obes Metab. 1999. PMID: 11221809 Clinical Trial.
Effects of estrogen/medrogestone therapy on the apoprotein B-containing lipoproteins in postmenopausal women with type 2 diabetes mellitus under satisfactory and non-satisfactory glycemic control.
Aguilar-Salinas CA, Arita Melzer O, Sauque Reyna L, Lopez A, Velasco Perez ML, Guillen LE, Gomez Perez FJ, Rull Rodrigo JA. Aguilar-Salinas CA, et al. Among authors: guillen le. Isr Med Assoc J. 2001 Feb;3(2):137-43. Isr Med Assoc J. 2001. PMID: 11344825 Free article. Clinical Trial.
Development and validation of a predictive model for incident type 2 diabetes in middle-aged Mexican adults: the metabolic syndrome cohort.
Arellano-Campos O, Gómez-Velasco DV, Bello-Chavolla OY, Cruz-Bautista I, Melgarejo-Hernandez MA, Muñoz-Hernandez L, Guillén LE, Garduño-Garcia JJ, Alvirde U, Ono-Yoshikawa Y, Choza-Romero R, Sauque-Reyna L, Garay-Sevilla ME, Malacara-Hernandez JM, Tusie-Luna MT, Gutierrez-Robledo LM, Gómez-Pérez FJ, Rojas R, Aguilar-Salinas CA. Arellano-Campos O, et al. Among authors: guillen le. BMC Endocr Disord. 2019 Apr 28;19(1):41. doi: 10.1186/s12902-019-0361-8. BMC Endocr Disord. 2019. PMID: 31030672 Free PMC article.
Clinical characterization of data-driven diabetes subgroups in Mexicans using a reproducible machine learning approach.
Bello-Chavolla OY, Bahena-López JP, Vargas-Vázquez A, Antonio-Villa NE, Márquez-Salinas A, Fermín-Martínez CA, Rojas R, Mehta R, Cruz-Bautista I, Hernández-Jiménez S, García-Ulloa AC, Almeda-Valdes P, Aguilar-Salinas CA; Metabolic Syndrome Study Group; Group of Study CAIPaDi. Bello-Chavolla OY, et al. BMJ Open Diabetes Res Care. 2020 Jul;8(1):e001550. doi: 10.1136/bmjdrc-2020-001550. BMJ Open Diabetes Res Care. 2020. PMID: 32699108 Free PMC article.
Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution.
Gómez-Pérez FJ, Aguilar-Salinas CA, Vázquez-Chávez C, Fanghänel-Salmón G, Gallegos-Martínez J, Gómez-Diaz RA, Salinas-Orozco S, Chavira-López IJ, Sánchez-Reyes L, Torres-Acosta EM, Tamez R, López A, Guillén LE, Cesarman G. Gómez-Pérez FJ, et al. Among authors: guillen le. Metabolism. 2002 Jan;51(1):44-51. doi: 10.1053/meta.2002.29024. Metabolism. 2002. PMID: 11782871 Clinical Trial.
The apolipoprotein E4 allele is not associated with an abnormal lipid profile in a Native American population following its traditional lifestyle.
Aguilar CA, Talavera G, Ordovas JM, Barriguete JA, Guillén LE, Leco ME, Pedro-Botet J, Gonzalez-Barranco J, Gómez-Pérez FJ, Rull JA. Aguilar CA, et al. Among authors: guillen le. Atherosclerosis. 1999 Feb;142(2):409-14. doi: 10.1016/s0021-9150(98)00251-2. Atherosclerosis. 1999. PMID: 10030393 Clinical Trial.
Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study.
Aguilar-Salinas CA, Gómez-Pérez FJ, Posadas-Romero C, Vázquez-Chávez C, Meaney E, Gulías-Herrero A, Guillén LE, Alvarado Vega A, Mendoza Pérez E, Eduardo Romero-Nava L, Angélica Gómez-Díaz R, Salinas-Orozco S, Moguel R, Novoa G. Aguilar-Salinas CA, et al. Among authors: guillen le. Atherosclerosis. 2000 Oct;152(2):489-96. doi: 10.1016/s0021-9150(99)00502-x. Atherosclerosis. 2000. PMID: 10998478 Clinical Trial.
Prediction of incident hypertension and arterial stiffness using the non-insulin-based metabolic score for insulin resistance (METS-IR) index.
Bello-Chavolla OY, Antonio-Villa NE, Vargas-Vázquez A, Martagón AJ, Mehta R, Arellano-Campos O, Gómez-Velasco DV, Almeda-Valdés P, Cruz-Bautista I, Melgarejo-Hernandez MA, Muñoz-Hernandez L, Guillén LE, Garduño-García JJ, Alvirde U, Ono-Yoshikawa Y, Choza-Romero R, Sauque-Reyna L, Garay-Sevilla ME, Malacara-Hernandez JM, Tusié-Luna MT, Gutierrez-Robledo LM, Gómez-Pérez FJ, Rojas R, Aguilar-Salinas CA. Bello-Chavolla OY, et al. Among authors: guillen le. J Clin Hypertens (Greenwich). 2019 Aug;21(8):1063-1070. doi: 10.1111/jch.13614. Epub 2019 Jul 18. J Clin Hypertens (Greenwich). 2019. PMID: 31318156 Free PMC article.
13 results